Medical News Today: A guide to psoriatic arthritis medication

Medications can relieve the symptoms of psoriatic arthritis, slow disease progression, and reduce or prevent joint damage. We explore the current treatments and medication advances here.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

Related Links:

ATLANTA—As many rheumatologists will recall, it was not too long ago that psoriatic arthritis was regarded somewhat like “rheumatoid arthritis with a rash,” with little attention paid to the ways in which the unique pathophysiology and manifestations of this entity make it distinct from other forms of inflammatory arthritis. At the 2019 ACR/ARP Annual Meeting... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: 2019 ACR/ARP Annual Meeting Conditions psoriatic arthritis Source Type: research
ATLANTA—Encouraging data on interleukin (IL) 23/IL-17 pathway drugs in psoriatic arthritis (PsA), JAK inhibitors in rheumatoid arthritis (RA) treatment and new evidence on physical activity and bone health in women were among the highlights of the 2019 ACR/ARP Annual Meeting’s Clinical Year in Review. Susan Manzi, MD, MPH, director of the Lupus Center for Excellence... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: 2019 ACR/ARP Annual Meeting Conditions Osteoarthritis bone fracture JAK inhibitors Knee Osteoarthritis (OA) physical activity psoriatic arthritis Research Source Type: research
ConclusionThe safety profile of adalimumab was consistent with previous findings and no new safety signals were observed.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
In this report, we have analysed disease outcomes in PsA by age groups.MethodsThis cross-sectional, multicentre study included 227 PsA patients under biological and non-biological systemic therapies. The study population was divided into four categories by age:    65 years. Physical functioning, disease activity, remission rates and disease impact were compared.ResultsThirty-one patients (13.7%) were under 40  years, 26.9% (n = 61) were 40–49 years, 26.4% (n = 60) were 50–65 years and 33.0% (n = 75) were patients >  65&...
Source: Drugs and Aging - Category: Geriatrics Source Type: research
AbstractDespite a ballooning therapeutic tool box, treatment responses to newer biologic agents and oral small molecules in psoriatic arthritis (PsA) and spondyloarthritis (SpA) are of similar magnitude to those observed with anti ‐Tumor Necrosis Factor (TNF) medications (1, 2).The PsA and SpA therapeutic outcomes stand in marked contrast to those reported in psoriasis where blockade of molecules in the IL‐23/IL‐17 pathway often provide prolonged, deep responses and in some cases even remission (3). The underlying mecha nisms that account for these divergent outcomes in the skin and joint are not well understood and ...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Editorial Source Type: research
Publication date: Available online 15 November 2019Source: Autoimmunity ReviewsAuthor(s): José María G. Ruiz de Morales, Lluís Puig, Esteban Daudén, Juan D. Cañete, José Luis Pablos, Antonio Olveira Martín, Carlos González Juanatey, Alfredo Adán, Xavier Montalbán, Natalia Borruel, Guillermo Ortí, Esther Holgado Martín, Carolina García-Vidal, Cynthia Vizcaya Morales, Víctor Martín Vázquez, Miguel Ángel González-GayAbstractInterleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of...
Source: Autoimmunity Reviews - Category: Allergy & Immunology Source Type: research
CONCLUSION: PsA patients are more frequently reclassified into the very-high SCORE risk category following carotid ultrasound assessment than controls. This was independently explained by the disease activity. PMID: 31732555 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Tags: J Rheumatol Source Type: research
AbstractObjectiveTo characterize the ecological effects of biologic therapies on the gut bacterial and fungal microbiome of psoriatic arthritis (PsA)/spondyloarthritis (SpA) patients.MethodsFecal samples from PsA/SpA patients pre ‐ and post‐treatment with tumor necrosis factor inhibitors (TNFi; n=15) or an anti‐interleukin (IL)‐17A monoclonal antibody inhibitor (IL‐17i; n=14) underwent sequencing (16S, ITS and shotgun metagenomics) and computational microbiome analysis. Fecal levels of fatty acid metabolites and cy tokines/proteins implicated in PsA/SpA pathogenesis or intestinal inflammation were correlated with...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Full Length Source Type: research
In conclusion, the PEST-bp questionnaire proved to be suitable as a screening tool for PsA in patients with psoriasis. Elevated PEST-bp scores are associated with decreased patient quality of life.
Source: Archives of Dermatological Research - Category: Dermatology Source Type: research
Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis INDIANAPOLIS, Nov. 12, 2019 -- (Healthcare Sales &Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today the 52-w... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, psoriatic arthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Arthritis | Health | Psoriatic Arthritis | Rheumatology